SPAC17A2.02c Antibody

What is SPAC17A2.02c and why is it significant in research?

SPAC17A2.02c, also known as Tlc4, is a conserved protein in Schizosaccharomyces pombe (fission yeast) that functions as a ceramide synthase (CerS) homolog. It is significant in research because it plays a crucial role in maintaining nuclear envelope (NE) integrity. Recent studies have shown that this protein suppresses nuclear envelope defects in cells lacking the NE proteins Lem2 and Bqt4 .

Unlike typical CerS proteins, Tlc4 functions through its non-catalytic activity while still possessing the characteristic TRAM/LAG1/CLN8 domain conserved in ceramide synthase proteins. Its unique localization pattern at both the nuclear envelope/endoplasmic reticulum and the cis- and medial-Golgi cisternae makes it an interesting subject for studying membrane dynamics and nuclear integrity maintenance mechanisms .

What are the key characteristics of commercially available SPAC17A2.02c antibodies?

Commercially available SPAC17A2.02c antibodies typically possess the following characteristics:

These antibodies are typically produced using recombinant S. pombe SPAC17A2.02c protein as the immunogen and are intended for research use only, not for diagnostic or therapeutic applications .

What are the optimal conditions for using SPAC17A2.02c antibody in Western blotting experiments?

For optimal Western blotting using SPAC17A2.02c antibody, follow this methodology:

• Sample preparation: Extract total proteins from S. pombe cells using a buffer containing protease inhibitors.

• SDS-PAGE: Separate proteins using 6-10% SDS-PAGE depending on your specific experimental needs.

• Transfer: Transfer proteins to PVDF membranes using standard transfer protocols.

• Blocking: Block membranes with 5% non-fat dry milk in TBST (TBS with 0.1% Tween-20) for 1 hour at room temperature.

• Primary antibody: Dilute SPAC17A2.02c antibody 1:1000 in blocking solution and incubate overnight at 4°C.

• Washing: Wash membranes 3-5 times with TBST for 5 minutes each.

• Secondary antibody: Incubate with HRP-conjugated anti-rabbit IgG (1:10,000 dilution) for 1 hour at room temperature.

• Detection: Visualize using enhanced chemiluminescence (ECL) substrate.

This protocol is adapted from methods used for similar membrane-associated protein detection in S. pombe . Adjustments may be needed based on protein expression levels and specific experimental requirements.

How can SPAC17A2.02c antibody be used in immunofluorescence assays to study localization patterns?

For immunofluorescence studies with SPAC17A2.02c antibody, implement the following protocol:

• Cell fixation: Fix S. pombe cells with 4% paraformaldehyde for 30 minutes at room temperature.

• Permeabilization: Treat cells with 0.5% Triton X-100 to allow antibody access to intracellular structures.

• Blocking: Block with 5% BSA in PBS for 1 hour to reduce non-specific binding.

• Primary antibody: Incubate with SPAC17A2.02c antibody (1:200 dilution) overnight at 4°C.

• Washing: Wash 3-5 times with PBS.

• Secondary antibody: Apply fluorophore-conjugated secondary antibody (e.g., Alexa Fluor 488) at 1:500 dilution for 1 hour at room temperature.

• Nuclear staining: Include DAPI (1:1000) for nuclear visualization.

• Mounting and visualization: Mount slides and visualize using fluorescence microscopy at appropriate excitation wavelengths (405 nm for DAPI, 488 nm for Alexa Fluor 488).

This method allows visualization of SPAC17A2.02c/Tlc4 localization at the nuclear envelope, endoplasmic reticulum, and Golgi apparatus. Co-staining with organelle markers (e.g., markers for the nuclear envelope, ER, or Golgi) can provide additional confirmation of localization patterns .

How does the function of SPAC17A2.02c/Tlc4 differ from conventional ceramide synthases, and what methodologies can distinguish its non-catalytic activities?

Unlike conventional ceramide synthases that primarily catalyze the synthesis of ceramides, SPAC17A2.02c/Tlc4 functions through non-catalytic activities to maintain nuclear envelope integrity. To distinguish these functions, researchers can implement the following methodological approaches:

• Mutational analysis: Create point mutations in the conserved TRAM/LAG1/CLN8 domain while preserving protein structure. Compare the function of these mutants with wild-type Tlc4 in complementation assays to determine which residues are essential for its non-catalytic function versus potential residual catalytic activity.

• In vitro enzymatic assays: Compare the ceramide synthase activity of purified Tlc4 with known CerS proteins using radiolabeled substrates. Minimal or absent catalytic activity despite structural homology would support its non-catalytic role.

• Interaction studies: Use co-immunoprecipitation with SPAC17A2.02c antibody followed by mass spectrometry to identify protein interaction partners that might explain its non-catalytic functions in maintaining nuclear envelope integrity.

• Localization-function analysis: Create chimeric proteins by swapping the localization signals of Tlc4 with those directing proteins exclusively to specific compartments (NE, ER, or Golgi). This approach can determine whether Tlc4's function is dependent on its ability to translocate between these compartments .

Research has shown that Golgi localization of Tlc4 is tightly linked to its activity in suppressing defects in Lem2 and Bqt4 double-deletion mutants, suggesting Tlc4's function may involve membrane trafficking between cellular compartments rather than direct enzymatic activity .

What role does SPAC17A2.02c/Tlc4 play in nuclear envelope maintenance, and how can researchers quantitatively assess this function?

SPAC17A2.02c/Tlc4 plays a critical role in maintaining nuclear envelope integrity, particularly in cells lacking the nuclear envelope proteins Lem2 and Bqt4. To quantitatively assess this function, researchers can implement these methodologies:

• Nuclear morphology analysis:

  • Stain cells with DAPI and measure nuclear morphology parameters (circularity, area, aspect ratio) in wild-type, tlc4Δ, lem2Δ bqt4Δ, and tlc4Δ lem2Δ bqt4Δ strains.

  • Quantify the percentage of cells showing nuclear envelope defects in each strain using fluorescence microscopy.

• Nuclear leakage assays:

  • Express GFP-tagged nuclear proteins and monitor their cytoplasmic mislocalization as an indicator of nuclear envelope permeability.

  • Measure the nuclear-to-cytoplasmic ratio of fluorescence intensity to quantify leakage.

• Electron microscopy analysis:

  • Use transmission electron microscopy to visualize nuclear envelope ultrastructure.

  • Quantify nuclear pore complex density and nuclear envelope discontinuities.

• Complementation experiments:

  • Express wild-type or mutant versions of Tlc4 in tlc4Δ lem2Δ bqt4Δ cells.

  • Quantify the rescue of nuclear envelope defects to identify functional domains.

Research indicates that Lem2 and Bqt4 likely control the translocation of Tlc4 from the nuclear envelope to the Golgi, which is necessary for maintaining nuclear envelope integrity. This translocation process represents a novel mechanism in nuclear envelope maintenance distinct from direct structural roles of other nuclear envelope proteins .

What are the common pitfalls when working with SPAC17A2.02c antibody, and how can researchers optimize specificity in their experiments?

When working with SPAC17A2.02c antibody, researchers may encounter several challenges. Here are common pitfalls and optimization strategies:

• Cross-reactivity issues:

  • Problem: Non-specific binding to other proteins with similar domains.

  • Solution: Include additional blocking steps with 5% BSA + 1% normal serum from the secondary antibody host species. Validate specificity using a tlc4Δ strain as a negative control.

• Weak signal detection:

  • Problem: Low abundance of endogenous SPAC17A2.02c/Tlc4.

  • Solution: Use enhanced chemiluminescence substrates for Western blot or signal amplification systems for immunofluorescence. Consider using epitope-tagged versions of Tlc4 for preliminary studies.

• Background signal:

  • Problem: High background obscuring specific signals.

  • Solution: Optimize antibody concentration through titration experiments (test dilutions from 1:500 to 1:5000). Extend washing steps and include 0.2% Tween-20 in wash buffers.

• Epitope masking:

  • Problem: Protein-protein interactions hiding the antibody epitope.

  • Solution: Test different extraction and fixation methods that might expose the epitope without denaturing the protein completely.

• Validation strategy:

  • Always include appropriate controls: (1) tlc4Δ strain, (2) pre-immune serum, and (3) peptide competition assay where the antibody is pre-incubated with excess antigen peptide before application.

These optimization strategies can significantly improve the specificity and sensitivity of experiments using SPAC17A2.02c antibody, leading to more reliable and reproducible results.

How can researchers develop robust epitope mapping strategies for SPAC17A2.02c antibodies to improve experimental design?

Developing robust epitope mapping for SPAC17A2.02c antibodies can significantly enhance experimental design. Researchers can implement the following methodological approach:

• Peptide array analysis:

  • Synthesize overlapping peptides (15-20 amino acids with 5-amino acid overlaps) spanning the entire SPAC17A2.02c/Tlc4 sequence.

  • Spot these peptides onto membranes and probe with the antibody.

  • Identify reactive peptides to narrow down the epitope region.

• Truncation analysis:

  • Create a series of N-terminal and C-terminal truncation mutants of Tlc4.

  • Express these truncated versions in an expression system.

  • Perform Western blot analysis to identify the minimal region recognized by the antibody.

• Alanine scanning mutagenesis:

  • Once a candidate epitope region is identified, create point mutations where consecutive amino acids are replaced with alanine.

  • Test antibody binding to identify critical residues for recognition.

• Cross-species conservation analysis:

  • Compare the identified epitope sequence with homologous proteins in related species.

  • Test the antibody against these homologs to assess cross-reactivity and epitope conservation.

Learning from epitope mapping techniques used for other proteins, such as those applied to identify the 72KPPPSYY78 epitope in African swine fever virus p17 protein , researchers can apply similar techniques to map SPAC17A2.02c antibody epitopes. This knowledge allows for:

• Development of more specific antibodies targeting non-conserved regions

• Creation of blocking peptides for validation experiments

• Better experimental design when using multiple antibodies simultaneously

• Understanding potential cross-reactivity with other TRAM/LAG1/CLN8 domain-containing proteins

How can SPAC17A2.02c antibody be utilized in studies investigating the relationship between lipid metabolism and nuclear envelope dynamics?

SPAC17A2.02c/Tlc4 represents an intriguing intersection between lipid metabolism enzymes (ceramide synthases) and nuclear envelope maintenance. Researchers can utilize SPAC17A2.02c antibody in the following methodological approaches:

• Co-localization studies with lipid probes:

  • Use fluorescently labeled ceramide analogs alongside immunofluorescence with SPAC17A2.02c antibody.

  • Analyze temporal and spatial relationships between ceramide accumulation and Tlc4 localization during cell cycle progression or stress responses.

• Proximity labeling approaches:

  • Create fusion proteins of Tlc4 with proximity labeling enzymes (BioID or APEX2).

  • Use SPAC17A2.02c antibody for validation and co-localization studies.

  • Identify proteins and lipids in proximity to Tlc4 under different conditions.

• Lipidomic analysis coupled with protein localization:

  • Fractionate cellular components (NE, ER, Golgi) using differential centrifugation.

  • Confirm fraction purity using SPAC17A2.02c antibody and organelle markers.

  • Perform lipidomic analysis of these fractions to correlate Tlc4 localization with lipid composition changes.

• Membrane fluidity and dynamics studies:

  • Use FRAP (Fluorescence Recovery After Photobleaching) or BiFC (Bimolecular Fluorescence Complementation) combined with SPAC17A2.02c antibody staining.

  • Analyze how lipid composition affects Tlc4 mobility and function at different cellular membranes.

These approaches can help elucidate whether Tlc4, despite functioning through non-catalytic mechanisms, influences lipid composition or organization that indirectly impacts nuclear envelope integrity, potentially revealing novel mechanisms of nuclear-cytoplasmic compartmentalization .

What strategies can researchers employ to develop high-affinity monoclonal antibodies against SPAC17A2.02c for advanced imaging techniques?

Developing high-affinity monoclonal antibodies against SPAC17A2.02c would greatly enhance advanced imaging applications. Researchers can employ these methodological strategies:

• Optimized immunization protocols:

  • Utilize recombinant SPAC17A2.02c fragments without transmembrane domains to improve immunogenicity.

  • Implement prime-boost strategies with alternating adjuvants to enhance antibody diversity.

  • Consider DNA immunization followed by protein boosting to increase the likelihood of generating high-affinity antibodies.

• Advanced hybridoma screening:

  • Implement competitive ELISA screening to identify high-affinity clones early in the selection process.

  • Use surface plasmon resonance (SPR) for quantitative affinity measurement of hybridoma supernatants.

  • Screen directly for functionality in immunofluorescence applications rather than just binding.

• Antibody engineering approaches:

  • Apply techniques similar to those used for therapeutic antibodies to enhance affinity:

  • Consider CDR (Complementarity-Determining Region) optimization through targeted mutagenesis.

  • Implement phage display with affinity maturation to improve binding characteristics.

• Validation for super-resolution microscopy:

  • Test candidates specifically for performance in STORM, PALM, or STED microscopy.

  • Optimize labeling density, fluorophore conjugation methods, and signal-to-noise ratio.

  • Validate antibody performance using known localization patterns of SPAC17A2.02c/Tlc4.

• Epitope binning strategy:

  • Generate antibodies targeting different epitopes of SPAC17A2.02c.

  • Identify non-competing antibody pairs for sandwich assays.

  • Develop multiplexed imaging approaches using differentially labeled antibodies.

Drawing from successes in developing high-affinity antibodies for other research applications , these methodologies can yield superior reagents for studying SPAC17A2.02c, particularly for advanced microscopy techniques that require high signal-to-noise ratios and specific labeling.

How does the experimental approach for SPAC17A2.02c antibody applications compare with antibody-based studies of other membrane-associated proteins?

When comparing experimental approaches for SPAC17A2.02c antibody applications with those of other membrane-associated proteins, researchers should consider these methodological differences and similarities:

The unique dual localization of SPAC17A2.02c/Tlc4 at both the nuclear envelope/ER and Golgi apparatus presents both challenges and opportunities compared to proteins restricted to a single membrane compartment. This requires careful experimental design to capture the dynamic nature of Tlc4's localization and function .

Studies of other membrane proteins, such as the work on NaPi2b (SLC34A2) antibodies , provide valuable methodological insights that can be adapted for SPAC17A2.02c research, particularly regarding membrane protein conformation preservation during antibody applications.

What lessons can researchers apply from antibody development against viral proteins to improve SPAC17A2.02c antibody specificity and functionality?

Researchers can apply several valuable lessons from viral protein antibody development to enhance SPAC17A2.02c antibody work:

• Epitope mapping and conservation analysis:

  • The approach used to identify the conserved 72KPPPSYY78 epitope in African swine fever virus p17 protein demonstrates how precise epitope identification can lead to highly specific antibodies.

  • Researchers should map epitopes of SPAC17A2.02c antibodies and assess conservation across related proteins to predict and prevent cross-reactivity.

• Antibody cocktail strategy:

  • The synergistic neutralization achieved by antibody cocktails against SARS-CoV-2 illustrates how multiple antibodies targeting different epitopes can provide superior results.

  • Consider developing combinations of SPAC17A2.02c antibodies targeting different domains for enhanced detection sensitivity and specificity.

• Structure-guided antibody selection:

  • The rational development of therapeutic antibodies using structural information about antigen-antibody interfaces can inform selection of optimal SPAC17A2.02c antibodies.

  • Use structural prediction tools like AlphaFold2 to model SPAC17A2.02c structure and identify accessible epitopes, similar to approaches used for viral proteins.

• Validation in multiple assay formats:

  • Comprehensive validation of antibodies in multiple assay formats (ELISA, Western blot, immunofluorescence) as demonstrated in viral antibody studies ensures reliability.

  • Implement rigorous validation protocols for SPAC17A2.02c antibodies across diverse experimental conditions.

• Quantitative affinity measurements:

  • The precise affinity measurements used in therapeutic antibody development (e.g., SPR with EC50 values in picomolar range) should be applied to research antibodies.

  • Quantify SPAC17A2.02c antibody affinities to select optimal reagents for specific applications and to ensure experimental reproducibility.